

Peptide	SEQ ID NO:	5 $\mu$ M	10 $\mu$ M	20 $\mu$ M
FQGV $\underline{\text{L}}$ QNVRFVF	6	2 $\pm$ 5	17 $\pm$ 7	37 $\pm$ 9
FQGV $\underline{\text{LQ}}$ AVRFVF	10	3 $\pm$ 4	4 $\pm$ 6	15 $\pm$ 7
FQGV $\underline{\text{LQNV}}$ AFVF	11	3 $\pm$ 3	5 $\pm$ 3	2 $\pm$ 5
F $\underline{\text{A}}$ GV $\underline{\text{LQNV}}$ RFVF	26	5 $\pm$ 2	9 $\pm$ 3	12 $\pm$ 4
D-ri-FQGV $\underline{\text{LQNV}}$ RFVF	-	5 $\pm$ 4	25 $\pm$ 13	39 $\pm$ 13

--

Please insert the accompanying paper copy of the Sequence Listing, page numbers 1 to 14, at the end of the application.

**In the Claims:**

Please amend claims 1, 3, 4 and 5 as follows:

1. (Amended) A peptide comprising the sequence R<sub>1</sub>-X<sub>1</sub>-X<sub>2</sub>-X<sub>3</sub>-X<sub>4</sub>-R<sub>2</sub>, wherein X<sub>1</sub> is selected from the group consisting of N, Q, D and S; X<sub>2</sub> is selected from the group consisting of V, I and L; X<sub>3</sub> is selected from the group consisting of R and K; and X<sub>4</sub> is selected from the group consisting of V, I, L and F; R<sub>1</sub> is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R<sub>2</sub> is a peptide of 1 to 3 amino acids, a hydroxide or an amide, provided that the peptide does not comprise the sequence FQGV $\underline{\text{LQNV}}$ RFVF (SEQ ID NO:6) or FRGCVRNLRLSR (SEQ ID NO:12).

3. (Amended) The peptide of claim 1 wherein R<sub>1</sub> is a peptide comprising the sequence selected from the group consisting of FQGV $\underline{\text{LQ}}$  (SEQ ID NO:13),

FAGVLQ (SEQ ID NO:14), FQGVAQ (SEQ ID NO:15), FQGVLA (SEQ ID NO:16), and FQGVLN (SEQ ID NO:17).

4. (Amended) The peptide of claim 1 peptide comprising at least one sequence selected from the group consisting of FQGVLQNLRFVF (SEQ ID NO:18), FQGVLDVRFVF (SEQ ID NO:19), FQGVLQQVRFVF (SEQ ID NO:20), FQGVLSVRFVF (SEQ ID NO:21), acQGVLQNVRF (SEQ ID NO:22), FQGVLQNVKFVF (SEQ ID NO:23), FQGVLNNVRFVF (SEQ ID NO:24), AQGVLQNVRFVF (SEQ ID NO:25), FAGVLQNVRFVF (SEQ ID NO:26), FQGVAQNVRFVF (SEQ ID NO:27), FQGVLQNVRFVA (SEQ ID NO:28), FQGVLANVRFVF (SEQ ID NO:29), FQGVLQNVRFV (SEQ ID NO:30), QGVLQNVRFVF (SEQ ID NO:31), and FQGVLQNVRF (SEQ ID NO:32).

5. (Amended) The peptide of claim 1 wherein  $X_1$ - $X_2$ - $X_3$ - $X_4$  is selected from the group consisting of NVRF (SEQ ID NO:51), SVRF (SEQ ID NO:52), QVRF (SEQ ID NO:53), DVRF (SEQ ID NO:54) and NLRF (SEQ ID NO:55).

#### REMARKS

Claims 1-45 are pending in this application. Claims 1, 3, 4 and 5 have been amended. The amendments to claims 1, 3, 4 and 5 insert the assigned identifiers for SEQ ID NOS: designated in these claims. The peptide FQGVLQNVRFVF (SEQ ID NO:6) has been deleted from claim 4, since claim 1 specifically excluded this peptide.

In the amendment to **Table 5** on page 47, clarification of the D-amino acid content of the retro-inverso peptide analog "ri-FQGVLQNVRFVF" was inserted to produce "D-ri-FQGVLQNVRFVF", in accordance with the definition of a "D-reverse peptide" given on page 14, lines 5-7. Page 13, lines 22-30 also contains the definition for the term "retro inverso peptide" as used herein, which includes "a peptide...whose sequence is comprised partially or entirely of D-amino acids". No sequence identifier